Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [E89] to Caldesmon/CDM (HRP)
- Suitable for: WB
- Reacts with: Mouse, Human
- Conjugation: HRP
Product nameAnti-Caldesmon/CDM antibody [E89] (HRP)
See all Caldesmon/CDM primary antibodies
DescriptionRabbit monoclonal [E89] to Caldesmon/CDM (HRP)
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Mouse, Human
Predicted to work with: Rat
within Human Caldesmon/CDM aa 750 to the C-terminus. The exact sequence is proprietary. Synthetic phospho peptide corresponding to residues surrounding Ser789 of human Caldesmon. This antibody is NOT phospho-specific, however, and will recognize total endogenous protein.
Database link: Q05682
- WB: HeLa and NIH3T3 cell lysates
This product was previously labelled as Caldesmon
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. Store In the Dark.
Storage bufferpH: 7.40
Preservative: 0.1% 10% Proclin 300 Solution
Constituents: 30% Glycerol, 1% BSA, PBS
Concentration information loading...
PurityProtein A purified
- Anti-Caldesmon/CDM antibody [E89] (Alexa Fluor® 488) (ab208116)
- Anti-Caldesmon/CDM antibody [E89] (Alexa Fluor® 647) (ab208117)
- Anti-Caldesmon/CDM antibody [E89] (PE) (ab211580)
- Anti-Caldesmon/CDM antibody [E89] (Alexa Fluor® 555) (ab214629)
- Anti-Caldesmon/CDM antibody [E89] - BSA and Azide free (ab215275)
- Anti-Caldesmon/CDM antibody [E89] (ab32330)
Our Abpromise guarantee covers the use of ab208234 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/15000. Detects a band of approximately 75 kDa (predicted molecular weight: 93 kDa).|
FunctionActin- and myosin-binding protein implicated in the regulation of actomyosin interactions in smooth muscle and nonmuscle cells (could act as a bridge between myosin and actin filaments). Stimulates actin binding of tropomyosin which increases the stabilization of actin filament structure. In muscle tissues, inhibits the actomyosin ATPase by binding to F-actin. This inhibition is attenuated by calcium-calmodulin and is potentiated by tropomyosin. Interacts with actin, myosin, two molecules of tropomyosin and with calmodulin. Also play an essential role during cellular mitosis and receptor capping.
Tissue specificityHigh-molecular-weight caldesmon (isoform 1) is predominantly expressed in smooth muscles, whereas low-molecular-weight caldesmon (isoforms 2, 3, 4 and 5) are widely distributed in non-muscle tissues and cells. Not expressed in skeletal muscle or heart.
Sequence similaritiesBelongs to the caldesmon family.
DomainThe N-terminal part seems to be a myosin/calmodulin-binding domain, and the C-terminal a tropomyosin/actin/calmodulin-binding domain. These two domains are separated by a central helical region in the smooth-muscle form.
modificationsIn non-muscle cells, phosphorylation by CDK1 during mitosis causes caldesmon to dissociate from microfilaments. Phosphorylation reduces caldesmon binding to actin, myosin, and calmodulin as well as its inhibition of actomyosin ATPase activity. Phosphorylation also occurs in both quiescent and dividing smooth muscle cells with similar effects on the interaction with actin and calmodulin and on microfilaments reorganization.
Cellular localizationCytoplasm > cytoskeleton. Cytoplasm > myofibril. On thin filaments in smooth muscle and on stress fibers in fibroblasts (nonmuscle).
- Information by UniProt
- CAD antibody
- CALD 1 antibody
- CALD1 antibody
All lanes : Anti-Caldesmon/CDM antibody [E89] (HRP) (ab208234) at 1/5000 dilution
Lane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
Lane 2 : NIH 3T3 (Mouse) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 93 kDa
Observed band size: 75 kDa why is the actual band size different from the predicted?
Exposure time: 4 minutes
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab208234 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
ab208234 has not yet been referenced specifically in any publications.